DC Devices Closes $34M Series D Financing to Complete Clinical Evaluation of the First Transcatheter Device to Treat Diastolic Heart Failure

bluebird bio Acquires Precision Genome Engineering, a Privately Held Gene-Editing Company

Voyager Therapeutics Appoints Industry Veteran Robert G. Pietrusko, Pharm.D., to Senior Vice President of Regulatory Affairs

Zafgen Appoints New Member of Board of Directors

Foundation Medicine Offers FoundationOne® CareLine to Provide Personalized Assistance to Cancer Patients Seeking Access to Targeted Therapies

Zafgen, Inc. Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option

Editas Medicine Appoints Katrine S. Bosley to Chief Executive Officer

Rhythm Presents Clinical Data that RM-493 Increases Energy Expenditure in Obesity Study

Blueprint Medicines to Present at JMP Securities Healthcare Conference

Kala Pharmaceuticals Initiates Phase 3 Clinical Trial for Treatment of Post-Surgical Ocular Inflammation and Phase 2 Clinical Trial in Dry Eye Disease

Global Blood Therapeutics Names Ted W. Love as CEO

Groundbreaking Collaborative Clinical Trial Launched

Agios Pharmaceuticals Announces Orphan Drug Designation of AG-221 for Treatment of Acute Myelogenous Leukemia

New Agios Clinical Data from Ongoing Phase 1 Trial of AG-221 Continue to Show Complete and Durable Remissions in Patients with Difficult to Treat Hematologic Malignancies

bluebird bio Reports Rapid Transfusion Independence in Beta-Thalassemia Major Patients Treated with its LentiGlobin Product Candidate

Agios Pharmaceuticals Announces that Celgene Exercised its Option to License AG-221 Under Global Strategic Collaboration

NinePoint Medical Receives 2014 MDEA Silver Medal for NvisionVLE Imaging System Deficiency, a Rare, Hemolytic Anemia

SAGE Therapeutics Appoints James M. Frates to the Company’s Board of Directors

Agios Pharmaceuticals Initiates Multiple Ascending Dose Trial in Healthy Volunteers of AG-348 for the Potential Treatment of PK

bluebird bio to Host a Conference Call to Discuss Initial Results from the HGB-205 Study in Beta-Thalassemia Major Subjects

SAGE Therapeutics Presents Preliminary SAGE-547 Clinical Data at Epilepsy Pipeline Conference

Bristol-Myers Squibb and CytomX Therapeutics Announce Worldwide Collaboration to Develop Probody™ Therapeutics Against Multiple Immuno-Oncology Targets

Third Rock Ventures and The Column Group Launch Nurix with $25.1 Million Financing to Target Key Regulatory Pathway

Agios Pharmaceuticals Reports First Quarter 2014 Financial Results

Eleven Biotherapeutics to Report First Quarter 2014 Financial Results on May 15, 2014

Foundation Medicine Announces 2014 First Quarter Results and Recent Highlights

Eleven Biotherapeutics Presents Data on Novel Protein Therapeutics for Treatment of Front and Back of Eye Diseases at ARVO 2014 Annual Meeting

Foundation Medicine to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference

Rhythm Presents Positive Phase 2 Study Results for Ghrelin Prokinetic Relamorelin (RM-131) in Diabetic Gastroparesis

Rhythm Presents Positive GI Motility Results for Relamorelin (RM-131) in Phase 2 Chronic Constipation Study

SAGE Therapeutics Appoints Thomas D. Anderson as Chief Commercial Strategy Office

Eleven Biotherapeutics Appoints Gary Sternberg, M.D., M.B.A., as Executive Vice President Corporate and Business Development

SAGE Therapeutics Receives U.S. Orphan Drug Designation for Lead Compound SAGE-547 to Treat Status Epilepticus

Agios Pharmaceuticals to Webcast Conference Call of First Quarter 2014 Financial Results on May 8, 2014

Allena Pharmaceuticals Announces Positive Phase 1 Data of ALLN-177 for the Treatment of Kidney Stones

New Preclinical Data Demonstrate Kala Pharmaceuticals’ Topical LE-MPPÂ Provides Equal or Better Drug Exposure Compared to Lotemax®

New Clinical Data using the NvisionVLE™ Imaging System to be presented at Digestive Disease Week® 2014

Editas Medicine Co-founders Present Novel Methods for Improving Genome Editing Specificity in Two Nature Biotechnology Papers

Agios Initiates Phase 1 Study of AG-348, a First-in-class PKR Activator, for Pyruvate Kinase Deficiency

Alcresta Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Develop Point-of-Care Nutritional Products

Foundation Medicine Announces Timing for First Quarter 2014 Financial Results and Conference Call

PanOptica Raises $45 Million to Finance Clinical Development of Anti-VEGF Eye Drop for Wet AMD

Blueprint Medicines Presents Positive Data on First Selective FGFR4 Inhibitor

Agios Announces Initial Phase 1 Data Demonstrating Clinical Activity of AG-221, First-in-Class Inhibitor of IDH2 Mutations, in Patients with Advanced Blood Cancers

Foundation Medicine and Clovis Oncology Expand Collaboration to Develop Novel Companion Diagnostic for Rucaparib in Ovarian Cancer

Constellation Pharmaceuticals will give a presentation on EZH2 and exhibit posters on EZH2 and BET at the AACR Annual Meeting, April 5-9 in San Diego, CA.

Foundation Medicine Announces New Data Highlighting FoundationOneâ„¢ and FoundationOneâ„¢ Heme to be Presented at the AACR Annual Meeting 2014

Eleven Biotherapeutics Added to Russell Indexes on March 31, 2014

SAGE Therapeutics Appoints Howard H. Pien to the Company’s Board of Directors

SAGE Therapeutics Initiates Phase 1/2 Trial of SAGE-547 in Status Epilepticus